Compare Gap Inc (GAP) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Summit Therapeutics Inc — how do they compare? Gap Inc trades at $20.75 (market cap $7.30B), while Summit Therapeutics Inc trades at $14.29 (market cap $11.70B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Gap Inc pays a 3.45% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GAP | SMMT | |
|---|---|---|
Market Cap | $7.30B | $11.70B |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $29.32 |
52-Week Low | $18.35 | $13.05 |
Enterprise Value | $10.38B | $11.12B |
Dividend Yield | 3.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap Inc. (GAP) trades at $20.13, up 1.67% today, with a bullish technical signal but mixed moving averages. The company shows strong profitability with a 6.25% net income margin and 27.58% ROE, supported by positive earnings beats in recent quarters. Revenue has stabilized around $15B, and cash flow from operations remains robust at $1.49B for 2025. Recent news highlights Gap's digital transformation and Athleta brand turnaround efforts, though legal investigations present headwinds.
The stock appears undervalued with a P/E of 8.05 and consensus price target of $27.00, implying 34% upside. Key opportunities include earnings growth and margin expansion, but risks involve competitive pressures and ongoing legal probes. Analyst sentiment is mixed with 39.58% buy ratings, suggesting cautious optimism for value-oriented investors.
Summit Therapeutics (SMMT) trades at $14.51, down 6.21% today, with a bearish technical outlook despite positive clinical trial results for its lung cancer drug ivonescimab. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, but maintains strong analyst support with 14 buy ratings and a $15.57 consensus price target. Recent developments include the $105 million divestiture of ridinilazole to Biossil and upcoming Q2 2026 earnings.
SMMT presents a high-risk, binary investment case centered on ivonescimab's commercial potential. While analyst sentiment is bullish and recent trial data is promising, the company's significant losses, cash burn, and single-asset focus pose substantial risks. The stock's volatility and concentrated ownership create potential for sharp moves around clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
